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Peritoneal dissemination is a frequent cause of death in patients with gastrointestinal cancers. It is difficult to treat with conventional therapeutics, particularly when it proceeds to a late phase. Hence, there is a strong need to develop new treatment strategies for peritoneal dissemination, to improve patient survival.
Recently, a Japanese team from the National Institute of Radiological Sciences (National Institutes for Quantum and Radiological Science and Technology), National Cancer Center Hospital East, and Nihon Medi-Physics Co., Ltd. published a study in the journal Oncotarget [1] to address this problem.
In this study, Dr. Yoshii and her colleagues developed a novel and invocative treatment strategy, called an "integrated 64 Cu therapy" that used 64 Cu-intraperitoneal radioimmunotherapy (ipRIT), alone or in combination with positron emission tomography (PET)-guided surgery to treat early-and late-phase peritoneal dissemination in mouse models. To achieve this new strategy, they focused on a theranostic agent, a 64 Cu-labeled anti-epidermal growth factor receptor (EGFR) antibody cetuximab. Cetuximab is widely used in clinical practices for a large variety of cancers, because many malignant tumors show EGFR overexpression [2] . The significance of using 64 Culabeled cetuximab is that this probe can be simultaneously used for both imaging and therapy. 64 Cu is a radionuclide that uniquely emits positrons, which are used for PET imaging, and β -particles, and Auger electrons, which are used for therapy [3, 4] . By using 64 Cu as a radionuclide, the combination of ipRIT and PET-guided surgery can be realized with a single administration of 64 Cu-labeled cetuximab.
In the study from Dr. Yoshii et al., the investigators tested the efficacy of ipRIT using 64 Cu-labeled cetuximab in the first step and showed that this treatment effectively inhibited tumor growth and significantly prolonged survival with little toxicity, in mouse models with earlyphase peritoneal dissemination of small lesions from gastrointestinal cancers. In the second step, they examined the feasibility of the combination use of 64 Cu-ipRIT and PET-guided surgery using 64 Cu-labeled cetuximab to treat late-phase peritoneal dissemination in mouse models. In this combination therapy, 64 Cu-ipRIT is used for downstaging by treating small lesions, and OpenPETguided surgery is used for resecting large tumor masses. The authors demonstrated that the combination use of 64 Cu-ipRIT and OpenPET-guided surgery effectively inhibited tumor growth and significantly prolonged survival without major toxicity in mouse models with late-phase peritoneal dissemination from gastrointestinal cancers. Notably, to make PET-guided surgery feasible, the investigators utilized the world's first open-typed PET system, called OpenPET, which they have developed [5] . In this system, the detectors are arranged to generate an open space for surgical procedures. Additionally, to achieve real-time PET imaging under surgery, the system equips a high-speed image reconstruction system. These outstanding technologies enable real-time PET imaging. In this proof-of-concept study with mice, a small-sized OpenPET system was used. Recently, a large-sized OpenPET system for human use has been also developed by their institute [6] . Therefore, OpenPET-guided surgery will be feasible in clinical settings in the future.
Thus far, several clinical PET studies have reported the utility of 64 Cu-labeled agents for imaging in humans. Our group has reported that 64 Cu-labeled trastuzumab PET is a potential noninvasive procedure for the serial identification of metastatic brain lesions in patients with HER2-positive breast cancer [7] . The study suggests that PET imaging with 64 Cu-labeled antibody is a safe and feasible approach for outpatients. The use of 64 Culabeled agents for therapy is also promising. Preclinical studies have reported the therapeutic effectiveness of 64 Cu-labeled agents, including 64 Cu-ATSM [8] , and 64 Culabeled antibodies [9] . Recently, a first-in-human study of radionuclide therapy with 64 CuCl 2 was performed by a group of Europe, in which they showed that the patient experienced a remarkable reduction in tumor volume without side effects [10] . These studies support the usefulness and feasibility of 64 Cu-labeled agents in humans, for both imaging and therapeutic purposes. Based on these evidences, 64 Cu-ipRIT and PET-guided surgery, proposed by Dr. Yoshii et al., are also worthwhile for further preclinical and clinical development.
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